Back to top

KeyBanc Remains a Buy on Resmed (RMD)

KeyBanc analyst Brett Fishbin maintained a Buy rating on Resmed today. The company’s shares closed yesterday at $272.60. According to TipRanks, Fis...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ResMed Inc. (RMD)